FDA Grants EUA to InflaRx’s Anti-Inflammatory COVID-19 Treatment

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 05, 2023 at 10:32: AM
via The FDA has granted emergency use authorization (EUA) to InflaRx’s vilobelimab, now to be marketed as Gohibic, for hospitalized adult patients with COVID-19, the German biotech announced Tuesday.

article source
 

<



Similar threads

cafead
FDA grants first EUA for COVID next-generation sequencing
Replies
0
Views
118
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants EUA for device to wean patients off ventilators
Replies
0
Views
102
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants fast track designation to Life Molecular Imaging’s tau PET diagnostic
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants IND clearance for Find’s Phase I chronic optic neuropathy trial
Replies
0
Views
24
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants IND clearance for Galapagos’ non-Hodgkin lymphoma therapy trial
Replies
0
Views
8
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote